Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

Phase 3 Completed 110 enrolled Crucell Holland BV

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The study is to assess whether the influenza vaccine Inflexal V for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.

Timeline

Start: 2012-07
Primary completion: 2012-08
Completion: 2012-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Inflexal V	Vaccine	0.5 ml	Intramuscular

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

Summary

Timeline

Drugs

Indications